PurposeIn this study, we aimed to use advanced machine learning (ML) techniques, specifically transfer learning and Vision Transformers (ViTs), to accurately classify meningioma in brain MRI scans. ViTs process images similarly to how humans visually perceive details and are useful for analyzing complex medical images. Transfer learning is a technique that uses models previously trained on large datasets and adapts them to specific use cases. Using transfer learning, this study aimed to enhance the diagnostic accuracy of meningioma location and demonstrate the capabilities the new technology. ApproachWe used a Google ViT model pre-trained on ImageNet-21k (a dataset with 14 million images and 21,843 classes) and fine-tuned on ImageNet 2012 (a dataset with 1 million images and 1,000 classes). Using this model, which was pre-trained and fine-tuned on large datasets of images, allowed us to leverage the predictive capabilities of the model trained on those large datasets without needing to train an entirely new model specific to only meningioma MRI scans. Transfer learning was used to adapt the pre-trained ViT to our specific use case, being meningioma location classification, using a dataset of 1,094 images of T1, contrast-enhanced, and T2-weighted MRI scans of meningiomas sorted according to location in the brain, with 11 different classes. ResultsThe final model trained and adapted on the meningioma MRI dataset achieved an average validation accuracy of 98.17% and a test accuracy of 89.95%. ConclusionsThis study demonstrates the potential of ViTs in meningioma location classification, leveraging their ability to analyze spatial relationships in medical images. While transfer learning enabled effective adaptation with limited data, class imbalance affected classification performance. Future work should focus on expanding datasets and incorporating ensemble learning to improve diagnostic reliability.

BackgroundAccurate prognostication of mobility outcomes is essential to guide rehabilitation and manage patient expectations. The prognostic utility of neuroimaging and neurophysiological biomarkers remains uncertain when measured early post-stroke. This systematic review aimed to examine the prognostic capacity of early neuroimaging and neurophysiological biomarkers of mobility outcomes up to 24-months post-stroke. MethodsMEDLINE and EMBASE were searched from inception to June 2025. Cohort studies that reported neuroimaging or neurophysiological biomarkers measured [≤]14-days post-stroke and mobility outcome(s) assessed >14-days and [≤]24-months post-stroke were included. Biomarker analyses were classified by statistical analysis approach (association, discrimination/classification or validation). Magnitude of relevant statistical measures was used as the primary indicator of prognostic capacity. Risk of bias was assessed using the Quality in Prognostic Studies tool. Meta-analysis was not performed due to heterogeneity. ResultsTwenty reports from 18 independent study samples (n=2,160 participants) were included. Biomarkers were measured a median 7.5-days post-stroke, and outcomes were assessed between 1- and 12-months. Eighty-six biomarker analyses were identified (61 neuroimaging, 25 neurophysiological) and the majority used an association approach (88%). Few used discrimination/classification methods (11%), and only one conducted internal validation (1%); an MRI-based machine learning model which demonstrated excellent discrimination but still requires external validation. Structural and functional corticospinal tract integrity were frequently investigated, and most associations were small or non-significant. Lesion location and size were also commonly examined, but findings were inconsistent and often lacked magnitude reporting. Methodological limitations were common, including small sample sizes, moderate to high risk of bias, poor reporting of magnitudes, and heterogeneous outcome measures and follow-up time points. ConclusionsCurrent evidence provides limited support for early neuroimaging and neurophysiological biomarkers to prognosticate post-stroke mobility outcomes. Most analyses remain at the association stage, with minimal progress toward validation and clinical implementation. Advancing the field requires international collaboration using harmonized methodologies, standardised statistical reporting, and consistent outcome measures and timepoints. RegistrationURL: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42022350771.

Brain metastases represent one of the most common intracranial malignancies, yet early and accurate detection remains challenging, particularly in clinical datasets with limited availability of healthy controls. In this study, we developed a feature-based machine learning framework to classify patients with and without brain metastases using multi-modal clinical MRI scans. A dataset of 50 subjects from the UCSF Brain Metastases collection was analyzed, including pre- and post-contrast T1-weighted images and corresponding segmentation masks. We designed advanced feature extraction strategies capturing intensity, enhancement patterns, texture gradients, and histogram-based metrics, resulting in 44 quantitative descriptors per subject. To address the severe class imbalance (46 metastasis vs. 4 non-metastasis cases), we applied minority oversampling and noise-based augmentation, combined with stratified cross-validation. Among multiple classifiers, Random Forest consistently achieved the highest performance with an average accuracy of 96.7% and an area under the ROC curve (AUC) of 0.99 across five folds. The proposed approach highlights the potential of handcrafted radiomic-like features coupled with machine learning to improve metastasis detection in heterogeneous clinical MRI cohorts. These findings underscore the importance of methodological strategies for handling imbalanced data and support the integration of feature-based models as complementary tools for brain metastasis screening and research.

BackgroundBrain atrophy is a hallmark of multiple sclerosis (MS). For clinical translatability and individual-level predictions, brain atrophy needs to be put into context of the broader population, using reference or normative models. MethodsReference models of MRI-derived brain volumes were established from a large healthy control (HC) multi-cohort dataset (N=63 115, 51% females). The reference models were applied to two independent MS cohorts (N=362, T1w-scans=953, follow-up time up to 12 years) to assess deviations from the reference, defined as Z-values. We assessed the overlap of deviation profiles and their stability over time using individual-level transitions towards or out of significant reference deviation states (|Z|>1{middle dot}96). A negative binomial model was used for case-control comparisons of the number of extreme deviations. Linear models were used to assess differences in Z-score deviations between MS and propensity-matched HCs, and associations with clinical scores at baseline and over time. The utilized normative BrainReference models, scripts and usage instructions are freely available. FindingsWe identified a temporally stable, brain morphometric phenotype of MS. The right and left thalami most consistently showed significantly lower-than-reference volumes in MS (25% and 26% overlap across the sample). The number of such extreme smaller-than-reference values was 2{middle dot}70 in MS compared to HC (4{middle dot}51 versus 1{middle dot}67). Additional deviations indicated stronger disability (Expanded Disability Status Scale: {beta}=0{middle dot}22, 95% CI 0{middle dot}12 to 0{middle dot}32), Paced Auditory Serial Addition Test score ({beta}=-0{middle dot}27, 95% CI -0{middle dot}52 to -0{middle dot}02), and Fatigue Severity Score ({beta}=0{middle dot}29, 95% CI 0{middle dot}05 to 0{middle dot}53) at baseline, and over time with EDSS ({beta}=0{middle dot}07, 95% CI 0{middle dot}02 to 0{middle dot}13). We additionally provide detailed maps of reference-deviations and their associations with clinical assessments. InterpretationWe present a heterogenous brain phenotype of MS which is associated with clinical manifestations, and particularly implicating the thalamus. The findings offer potential to aid diagnosis and prognosis of MS. FundingNorwegian MS-union, Research Council of Norway (#223273; #324252); the South-Eastern Norway Regional Health Authority (#2022080); and the European Unions Horizon2020 Research and Innovation Programme (#847776, #802998). Research in contextO_ST_ABSEvidence before this studyC_ST_ABSReference values and normative models have yet to be widely applied to neuroimaging assessments of neurological disorders such as multiple sclerosis (MS). We conducted a literature search in PubMed and Embase (Jan 1, 2000-September 12, 2025) using the terms "MRI" AND "multiple sclerosis", with and without the keywords "normative model*" and "atrophy", without language restrictions. While normative models have been applied in psychiatric and developmental disorders, few studies have addressed their use in neurological conditions. Existing MS research has largely focused on global atrophy and has not provided regional reference charts or established links to clinical and cognitive outcomes. Added value of this studyWe provide regionally detailed brain morphometry maps derived from a heterogeneous MS cohort spanning wide ranges of age, sex, clinical phenotype, disease duration, disability, and scanner characteristics. By leveraging normative modelling, our approach enables individualised brain phenotyping of MS in relation to a population based normative sample. The analyses reveal clinically meaningful and spatially consistent patterns of smaller brain volumes, particularly in the thalamus and frontal cortical regions, which are linked to disability, cognitive impairment, and fatigue. Robustness across scanners, centres, and longitudinal follow-up supports the stability and generalisability of these findings to real-world MS populations. Implications of all the available evidenceNormative modelling offers an individualised, sensitive, and interpretable approach to quantifying brain structure in MS by providing individual-specific reference values, supporting earlier detection of neurodegeneration and improved patient stratification. A consistent pattern of thalamic and fronto-parietal deviations defines a distinct morphometric profile of MS, with potential utility for early and personalised diagnosis and disease monitoring in clinical practice and clinical trials.

Background and ObjectivesIdentifying MS in children early and distinguishing it from other neuroinflammatory conditions of childhood is critical, as early therapeutic intervention can improve outcomes. The anterior visual pathway has been demonstrated to be of central importance in diagnostic considerations for MS and has recently been identified as a fifth topography in the McDonald Diagnostic Criteria for MS. Optical coherence tomography (OCT) provides high-resolution retinal imaging and reflects the structural integrity of the retinal nerve fiber and ganglion cell inner plexiform layers. Whether multimodal deep learning models can use OCT alone to diagnose pediatric MS (POMS) is unknown. MethodsWe analyzed 3D OCT scans collected prospectively through the Neuroinflammatory Registry of the Hospital for Sick Children (REB#1000005356). Raw macular and optic nerve head images, and 52 automatically segmented features were included. We evaluated three classification approaches: (1) deep learning models (e.g. ResNet, DenseNet) for representation learning followed by classical ML classifiers, (2) ML models trained on OCT-derived features, and (3) multimodal models combining both via early and late fusion. ResultsScans from individuals with POMS (onset 16.0 {+/-} 3.1 years, 51.0%F; 211 scans) and 29 children with non-inflammatory neurological conditions (13.1 {+/-} 4.0 years, 69.0%F, 52 scans) were included. The early fusion model achieved the highest performance (AUC: 0.87, F1: 0.87, Accuracy: 90%), outperforming both unimodal and late fusion models. The best unimodal feature-based model (SVC) yielded an AUC of 0.84, F1 of 0.85 and an accuracy of 85%, while the best image-based model (ResNet101 with Random Forest) achieved an AUC of 0.87, F1 of 0.79, and accuracy of 84%. Late fusion underperformed, reaching 82% accuracy but failing in the minority class. DiscussionMultimodal learning with early fusion significantly enhances diagnostic performance by combining spatial retinal information with clinically relevant structural features. This approach captures complementary patterns associated with MS pathology and shows promise as an AI-driven tool to support pediatric neuroinflammatory diagnosis.

Automated thalamic nuclear segmentation has contributed towards a shift in neuroimaging analyses from treating the thalamus as a homogeneous, passive relay, to a set of individual nuclei, embedded within distinct brain-wide circuits. However, many studies continue to widely rely on FreeSurfers segmentation of T1-weighted structural MRIs, despite their poor intrathalamic nuclear contrast. Meanwhile, a convolutional neural network tool has been developed for FreeSurfer, using information from both diffusion and T1-weighted MRIs. Another popular thalamic nuclear segmentation technique is HIPS-THOMAS, a multi-atlas-based method that leverages white-matter-like contrast synthesized from T1-weighted MRIs. However, rigorous comparisons amongst methods remain scant, and the thalamic atlases against which these methods have been assessed have their own limitations. These issues may compromise the quality of cross-species comparisons, structural and functional connectivity studies in health and disease, as well as the efficacy of neuromodulatory interventions targeting the thalamus. Here, we report, for the first time, comparisons amongst HIPS-THOMAS, the standard FreeSurfer segmentation, and its more recent development, against two thalamic atlases as silver-standard ground-truths. We used two cohorts of healthy adults, and one cohort of patients in the chronic phase of autoimmune limbic encephalitis. In healthy adults, HIPS-THOMAS surpassed, not only the standard FreeSurfer segmentation, but also its more recent, diffusion-based update. The improvements made with the latter relative to the former were limited to a few nuclei. Finally, the standard FreeSurfer method underperformed, relative to the other two, in distinguishing between patients and healthy controls based on the affected anteroventral and pulvinar nuclei. In light of the above findings, we provide recommendations on the use of automated segmentation methods of the human thalamus using structural brain imaging.

BackgroundEarly detection of autism spectrum disorder (ASD) improves outcomes, yet clinical assessment is time-intensive. Artificial intelligence (AI) may support screening in preschool children by analysing behavioural, neurophysiological, imaging, and biomarker data. AimTo synthesise studies that applied AI in ASD assessment and evaluate whether the underlying data and AI approaches can distinguish ASD characteristics in early childhood. MethodsA systematic search of 15 databases was conducted on 30 November 2024 using predefined terms. Inclusion criteria were empirical studies applying AI to ASD detection in children aged 0-7 years. Reporting followed PRISMA 2020. ResultsTwelve studies met criteria. Reported performance (AUC) ranged from 0.65 to 0.997. Modalities included behavioural (eye-tracking, home videos), motor (tablet/reaching), EEG, diffusion MRI, and blood/epigenetic biomarkers. The largest archival dataset (M-CHAT-R) achieved near-perfect AUC with neural networks. Common limitations were small samples, male-skewed cohorts, and limited external validation. ConclusionsAI can aid early ASD screening in infants and preschoolers, but larger and more diverse datasets, rigorous external validation, and multimodal integration are needed before clinical deployment.

BackgroundAutomated interpretation of resting-state fMRI (rs-fMRI) for epilepsy diagnosis remains a challenge. We developed a regularized transformer that models parcel-wise spatial patterns and long-range temporal dynamics to classify epilepsy and generate interpretable, network-level candidate biomarkers. MethodsInputs were Schaefer-200 parcel time series extracted after standardized preprocessing (fMRIPrep). The Regularized Transformer is an attention-based sequence model with learned positional encoding and multi-head self-attention, combined with fMRI-specific regularization (dropout, weight decay, gradient clipping) and augmentation to improve robustness on modest clinical cohorts. Training used stratified group 4-fold cross-validation on n=65 (30 epilepsy, 35 controls) with fMRI-specific augmentation (time-warping, adaptive noise, structured masking). We compared the transformer to seven baselines (MLP, 1D-CNN, LSTM, CNN-LSTM, GCN, GAT, Attention-Only). External validation used an independent set (10 UNC epilepsy cohort, 10 controls). Biomarker discovery combined gradient-based attributions with parcelwise statistics and connectivity contrasts. ResultsOn an illustrative best-performing fold, the transformer attained Accuracy 0.77, Sensitivity 0.83, Specificity 0.88, F1-Score 0.77, and AUC 0.76. Averaged cross-validation performance was lower but consistent with these findings. External testing yielded Accuracy 0.60, AUC 0.64, Specificity 0.80, Sensitivity 0.40. Attribution-guided analysis identified distributed, network-level candidate biomarkers concentrated in limbic, somatomotor, default-mode and salience systems. ConclusionsA regularized transformer on parcel-level rs-fMRI can achieve strong within-fold discrimination and produce interpretable candidate biomarkers. Results are encouraging but preliminary larger multi-site validation, stability testing and multiple-comparison control are required prior to clinical translation.

Autism Spectrum Disorder (ASD) is a neurological condition that affects the brain, leading to challenges in speech, communication, social interaction, repetitive behaviors, and motor skills. This research aims to develop a deep learning based model for the accurate diagnosis and classification of autistic symptoms in children, thereby benefiting both patients and their families. Existing literature indicates that classification methods typically analyze region based summaries of Functional Magnetic Resonance Imaging (fMRI). However, few studies have explored the diagnosis of ASD using brain imaging. The complexity and heterogeneity of biomedical data modeling for big data analysis related to ASD remain unclear. In the present study, the Autism Brain Imaging Data Exchange 1 (ABIDE-1) dataset was utilized, comprising 1,112 participants, including 539 individuals with ASD and 573 controls from 17 different sites. The dataset, originally in NIfTI format, required conversion to a computer-readable extension. For ASD classification, the researcher proposed and implemented a VGG20 architecture. This deep learning VGG20 model was applied to neuroimages to distinguish ASD from the non ASD cases. Four evaluation metrics were employed which are recall, precision, F1-score, and accuracy. Experimental results indicated that the proposed model achieved an accuracy of 61%. Prior to this work, machine learning algorithms had been applied to the ABIDE-1 dataset, but deep learning techniques had not been extensively utilized for this dataset and the methods implied in this study as this research is conducted to facilitate the early diagnosis of ASD.

Purpose: Accurate detection and segmentation of brain metastases (BM) from MRI are critical for the appropriate management of cancer patients. This study investigates strategies to enhance the robustness of artificial intelligence (AI)-based BM detection and segmentation models. Method: A DeepMedic-based network with a loss function, tunable with a sensitivity/specificity tradeoff weighting factor \alpha- was trained on T1 post-contrast MRI datasets from two institutions (514 patients, 4520 lesions). Robustness was evaluated on an external dataset from a third institution dataset (91 patients, 397 lesions), featuring ground truth annotations from two physicians. We investigated the impact of loss function weighting factor, \alpha and training dataset combinations. Detection performance (sensitivity, precision, F1 score) and segmentation accuracy (Dice similarity, and 95% Hausdorff distance (HD95)) were evaluated using one physician contours as the reference standard. The optimal AI model was then directly compared to the performance of the second physician. Results: Varying demonstrated a trade-off between sensitivity (higher ) and precision (lower ), with =0.5 yielding the best F1 score (0.80 {+/-} 0.04 vs. 0.78 {+/-} 0.04 for =0.95 and 0.72 {+/-} 0.03 for =0.99) on the external dataset. The optimally trained model achieved detection performance comparable to the physician (F1: AI=0.83 {+/-} 0.04, Physician=0.83 {+/-} 0.04), but slightly underperformed in segmentation (Dice: 0.79 {+/-} 0.04 vs. AI=0.74 {+/-} 0.03; HD95: 2.8 {+/-} 0.14 mm vs. AI=3.18 {+/-} 0.16 mm, p<0.05). Conclusion: The derived optimal model achieves detection and segmentation performance comparable to an expert physician in a parallel comparison.